T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$4.01B |
| 2 |
Broadcom
AVGO
|
+$1.49B |
| 3 |
GE Vernova
GEV
|
+$1.19B |
| 4 |
International Paper
IP
|
+$1.05B |
| 5 |
SCHW
Charles Schwab
SCHW
|
+$952M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$2.31B |
| 2 |
Constellation Energy
CEG
|
+$1.94B |
| 3 |
Qualcomm
QCOM
|
+$1.74B |
| 4 |
NVIDIA
NVDA
|
+$1.71B |
| 5 |
Salesforce
CRM
|
+$1.5B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 33.98% |
| 2 | Healthcare | 14.89% |
| 3 | Financials | 10.35% |
| 4 | Consumer Discretionary | 10.11% |
| 5 | Communication Services | 9.23% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
851
Rollins
ROL
$17.4B
| $30.1M | ﹤0.01% |
616,348
+13,488
| +2% | +$623K |
|
|
BCPC
852
Balchem Corp
BCPC
$5.65B
| $30.1M | ﹤0.01% |
195,335
+2,189
| +1% | +$330K |
|
853
Grupo Aeroportuario del Sureste
ASR
$8.01B
| $29.9M | ﹤0.01% |
99,946
-2,829
| -3% | -$925K |
|
854
Sterling Infrastructure
STRL
$16.9B
| $29.7M | ﹤0.01% |
250,904
+221,448
| +752% | +$25.3M |
|
855
Payoneer
PAYO
$2.42B
| $29.5M | ﹤0.01% |
5,326,317
+535,917
| +11% | +$2.9M |
|
|
SPNS
856
DELISTED
Sapiens International
SPNS
| $29.3M | ﹤0.01% |
864,742
+9,205
| +1% | +$300K |
|
857
Enphase Energy
ENPH
$5.39B
| $29.3M | ﹤0.01% |
294,097
-112,270
| -28% | -$13.1M |
|
858
Workiva
WK
$4.01B
| $28.9M | ﹤0.01% |
395,301
+4,362
| +1% | +$343K |
|
859
First Industrial Realty Trust
FR
$8.4B
| $28.8M | ﹤0.01% |
606,434
-18,204
| -3% | -$872K |
|
860
Haemonetics
HAE
$4.11B
| $28.8M | ﹤0.01% |
348,061
-214,393
| -38% | -$18.9M |
|
861
Zai Lab
ZLAB
$2.92B
| $28.7M | ﹤0.01% |
1,657,915
+7,128
| +0.4% | +$125K |
|
862
Simply Good Foods
SMPL
$989M
| $28.5M | ﹤0.01% |
788,286
+680
| +0.1% | +$24.3K |
|
|
BOW
863
Bowhead Specialty Holdings
BOW
$1.1B
| $28.4M | ﹤0.01% |
+1,122,573
| New | +$28.7M |
|
864
Invitation Homes
INVH
$18B
| $28.4M | ﹤0.01% |
791,080
+19,707
| +3% | +$685K |
|
865
UFP Technologies
UFPT
$2.48B
| $28.2M | ﹤0.01% |
106,834
+63,700
| +148% | +$15.7M |
|
|
IGMS
866
DELISTED
IGM Biosciences
IGMS
| $28M | ﹤0.01% |
4,075,091
+187,068
| +5% | +$1.6M |
|
867
Iovance Biotherapeutics
IOVA
$2.95B
| $27.9M | ﹤0.01% |
3,482,402
-1,785,462
| -34% | -$19.1M |
|
868
Northern Trust
NTRS
$34.8B
| $27.9M | ﹤0.01% |
332,465
+254
| +0.1% | +$21.3K |
|
869
Intellia Therapeutics
NTLA
$1.66B
| $27.9M | ﹤0.01% |
1,244,959
-380,092
| -23% | -$9.05M |
|
870
Camtek
CAMT
$8.06B
| $27.7M | ﹤0.01% |
+221,393
| New | +$21.1M |
|
871
Synchrony
SYF
$26.1B
| $27.6M | ﹤0.01% |
585,059
-715,517
| -55% | -$31.1M |
|
872
Eversource Energy
ES
$27.2B
| $27.6M | ﹤0.01% |
486,318
+20,064
| +4% | +$1.19M |
|
|
CNR
873
Core Natural Resources Inc
CNR
$4.64B
| $27.4M | ﹤0.01% |
268,614
+250,270
| +1,364% | +$22.8M |
|
874
Genuine Parts
GPC
$18.7B
| $27.4M | ﹤0.01% |
197,962
+5,035
| +3% | +$751K |
|
875
Valvoline
VVV
$4.31B
| $27.3M | ﹤0.01% |
630,801
+76,485
| +14% | +$3.21M |
|
Similar funds
T. Rowe Price Associates's Q2 2024 Portfolio in Review
As of Q2 2024, T. Rowe Price Associates held 3,089 positions worth $836B, up 2.4% from $816B the previous quarter. Its ten largest holdings account for 36% of the portfolio.
T. Rowe Price Associates's Q2 2024 filing shows 135 new, 1,850 increased, 836 reduced and 113 closed positions. Its largest new stake was Tempus AI: 5,227,120 shares worth $183M. The largest sale was Microsoft, an estimated $2.31B.
By sector, the portfolio is most concentrated in Technology at 34% of assets, up from 32% a quarter earlier, followed by Healthcare and Financials.
- T. Rowe Price Associates's largest Q2 2024 buy was Tempus AI: 5,227,120 shares worth $183M.
- T. Rowe Price Associates added most to Apple in Q2 2024, an estimated $4.01B increase.
- T. Rowe Price Associates's biggest Q2 2024 reduction was Microsoft, cutting an estimated $2.31B.
- T. Rowe Price Associates fully exited Pioneer Natural Resource Co. in Q2 2024, selling an estimated $570M.
- T. Rowe Price Associates's ten largest holdings make up 36% of its $836B portfolio in Q2 2024.
- T. Rowe Price Associates opened 135 new positions and closed 113 in Q2 2024.
- T. Rowe Price Associates's portfolio value rose 2.4% quarter-over-quarter to $836B.
Based on T. Rowe Price Associates's 13F filing for Q2 2024, filed 14 Aug 2024.